Biometrics

Third-Party Banking Software Market Size to Grow USD 16620 Million by 2029 at a CAGR of 8.8% | Valuates Reports

Retrieved on: 
Tuesday, January 16, 2024

BANGALORE, India, Jan. 16, 2024 /PRNewswire/ -- The Third-Party Banking Software Market is Segmented by Type ( Core Banking Software , Multi-Channel Banking Software, BI Software , Private Wealth Management Software ), by Application ( Risk Management , Information Security, Business Intelligence , Training and Consulting Solutions).

Key Points: 
  • BANGALORE, India, Jan. 16, 2024 /PRNewswire/ -- The Third-Party Banking Software Market is Segmented by Type ( Core Banking Software , Multi-Channel Banking Software, BI Software , Private Wealth Management Software ), by Application ( Risk Management , Information Security, Business Intelligence , Training and Consulting Solutions).
  • The Global Third-Party Banking Software Market is projected to grow from USD 10050 Million in 2023 to USD 16620 Million by 2029, at a Compound Annual Growth Rate (CAGR) of 8.8% during the forecast period.
  • The need for regulatory technology (RegTech) solutions in third-party banking software has been driven by strict regulatory requirements and the increasing intricacy of compliance.
  • Third-party banking software companies now have more prospects as a result of the global expansion of open banking initiatives.

Onera raises over €30M in Series C funding

Retrieved on: 
Tuesday, January 16, 2024

Onera Health, pioneer and leader in remote sleep diagnostic and monitoring solutions enabling clinicians to conduct sleep studies anytime, anywhere, announced the completion of its Series C financing round.

Key Points: 
  • Onera Health, pioneer and leader in remote sleep diagnostic and monitoring solutions enabling clinicians to conduct sleep studies anytime, anywhere, announced the completion of its Series C financing round.
  • This latest funding round brings Onera’s total investment to date to more than €55 million.
  • View the full release here: https://www.businesswire.com/news/home/20240115279169/en/
    Ruben de Francisco, Founder and CEO of Onera Health.
  • As part of this transaction, Drew Burdon and Michaël Vlemmix will join Onera Health’s Board of Directors.

SimBioSys® Appoints Renowned Surgical Oncologist, Dr. Barry Rosen, as Chief Medical Officer Following First FDA Clearance for TumorSight™ Precision Medicine Platform

Retrieved on: 
Friday, January 12, 2024

This significant move coincides with the company's milestone achievement of receiving its first FDA clearance on its digital precision medicine platform, TumorSight™, and accelerating the development of additional offerings on the platform.

Key Points: 
  • This significant move coincides with the company's milestone achievement of receiving its first FDA clearance on its digital precision medicine platform, TumorSight™, and accelerating the development of additional offerings on the platform.
  • His addition comes at a crucial juncture as we bring TumorSight™ to market, expand our clinical portfolio and advance our groundbreaking research product, PhenoScope™.
  • In a previous article interviewing Dr. Rosen, he shared his thoughts on the need and impact TumorSight™ could have, starting with TumorSight™ Plan.
  • That's what we're striving for with breast cancer surgery - we have that level of technology already for home projects, but we don't have it yet for this field."

Bond Biosciences Announces Successful Pre-IND Meeting with the FDA to Advance the Development of BBI-001 for Treatment of Iron Overload Associated with Hereditary Hemochromatosis

Retrieved on: 
Thursday, January 11, 2024

BBI-001 is a novel investigational new drug.

Key Points: 
  • BBI-001 is a novel investigational new drug.
  • It is a non-absorbed, oral therapeutic designed to rapidly form a strong and selective iron chelate in the digestive tract, thus inhibiting iron absorption in patients with symptomatic iron overload due to HH.
  • The structure and properties of BBI-001 have been designed to restrict it to the GI tract to inhibit systemic expose.
  • “FDA was very thoughtful in reviewing the Bond briefing package and replying in depth on the proposed non-clinical and clinical development program options, to facilitate the next Phase of clinical development” observed Curtis L. Scribner, MD, Bond’s Chief Medical Officer.

Rune Labs Unveils $12 Million Strategic Round to Accelerate Adoption of Novel Parkinson’s Technologies

Retrieved on: 
Thursday, January 11, 2024

Rune Labs , a precision neurology software and data company, today announced a strategic round of $12 million, increasing the total amount raised by the company to over $42 million.

Key Points: 
  • Rune Labs , a precision neurology software and data company, today announced a strategic round of $12 million, increasing the total amount raised by the company to over $42 million.
  • Jordi Parramon, PhD, CEO, General Partner and Co-Founder of Nexus NeuroTech Ventures and former President of Medical Devices at Verily, will join Rune Labs’ board of directors.
  • “Focused on investing in technologies that can transform how we treat brain disorders, our aim at Nexus NeuroTech Ventures is to support innovative companies like Rune Labs.
  • I strongly believe that Rune Labs and their tool, StrivePD, are set to transform how we receive care and improve outcomes for many people living with Parkinson’s,” said Benjamin Stecher, Chair of the Patient Advisory Board at Rune Labs.

Reperio Health Enables Vanderbilt Health Employer Solutions to Add At-Home Screenings to its Growing Portfolio

Retrieved on: 
Wednesday, January 10, 2024

Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, announced today it is now fueling new at-home screening capabilities for Vanderbilt Health Employer Solutions (VHES), which provides innovative workforce health and wellness programs to businesses in the Mid-South and across the United States.

Key Points: 
  • Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, announced today it is now fueling new at-home screening capabilities for Vanderbilt Health Employer Solutions (VHES), which provides innovative workforce health and wellness programs to businesses in the Mid-South and across the United States.
  • Vanderbilt Health will now offer its employer clients access to Reperio’s full-service and comprehensive health screenings with instant results.
  • Reperio brings a patient-friendly experience to biometric health screenings, through patented technology that pairs a mobile app with FDA-cleared devices.
  • VHES has provided corporate health services, including on-site health screenings , to a diverse array of employers across the country for more than three decades.

BioConnect Acquires Silent Partner Technologies to Expand Offerings for Intelligent Asset Tracking and Inventory Management to Bring Security and Accountability to Critical Assets Ranging From Controlled Narcotics to First Responder Gear

Retrieved on: 
Wednesday, January 10, 2024

Portfolios of both companies complement each other perfectly.

Key Points: 
  • Portfolios of both companies complement each other perfectly.
  • “Bringing security and accountability to assets ranging from Narcotics and Controlled Goods to First Responder Gear and IT assets is becoming increasingly critical in today’s environment and in particular eliminating Drug Diversion feeding the Opioid crisis.
  • With the acquisition of Silent Partner Technologies, together we will offer a simple cloud subscription to upgrade any area protecting assets to become the next generation ‘Smart Space’ solution.
  • Customers looking for higher security and ‘chain of custody’ accountability to protect their critical assets will find this solution very compelling,” commented Rob Douglas, Founder and CEO of BioConnect.

World First: Continental Integrates Face Authentication Invisibly Behind Driver Display Console

Retrieved on: 
Wednesday, January 10, 2024

CES 2024 - Continental presents the “Face Authentication Display,” a two-stage access control system based on biometric user recognition that uses special camera systems mounted externally on the vehicle’s B-pillar and invisibly behind the driver display console.

Key Points: 
  • CES 2024 - Continental presents the “Face Authentication Display,” a two-stage access control system based on biometric user recognition that uses special camera systems mounted externally on the vehicle’s B-pillar and invisibly behind the driver display console.
  • Thanks to biometric face authentication, the vehicle opens and starts up as soon as it detects a registered user.
  • View the full release here: https://www.businesswire.com/news/home/20240110003816/en/
    Continental’s “Face Authentication Display” makes it possible to unlock the vehicle safely and conveniently using biometric facial recognition.
  • Together with Continental, we are improving existing driver monitoring systems and thus ensuring better interaction between the driver and the vehicle.

ID R&D Introduces Voice Clone Detection for Protection Against Gen AI-based Identity Fraud

Retrieved on: 
Tuesday, January 9, 2024

ID R&D, a Mitek company, and an award-winning provider of voice biometrics and liveness technology, today introduced voice clone detection as a new option for its IDLive® Voice liveness detection product.

Key Points: 
  • ID R&D, a Mitek company, and an award-winning provider of voice biometrics and liveness technology, today introduced voice clone detection as a new option for its IDLive® Voice liveness detection product.
  • Detecting voice clones and audio deepfakes can prevent fraud and crime, deter bad actors, and help preserve trust in the authenticity of digital audio communication.
  • The software processes a recording of speech and uses AI to determine whether it was spoken by a person or a voice clone.
  • “In a world where deepfake impersonations are proliferating so rapidly, voice clone detection plays an essential role in preserving trust between people and technology, securing the voice interface from fraud.”

ELGi Powers AIRLAB Fitness’ Simulated High-Altitude Fitness Training Facility in Miami, Florida

Retrieved on: 
Tuesday, January 9, 2024

The simulated high-altitude training environment is powered by ELGi’s EG37 Series screw air compressor within hypoxic air chambers from Australian-based Altitude Training Systems (ATS), a pioneer in altitude technology.

Key Points: 
  • The simulated high-altitude training environment is powered by ELGi’s EG37 Series screw air compressor within hypoxic air chambers from Australian-based Altitude Training Systems (ATS), a pioneer in altitude technology.
  • Co-CEO of AIRLAB Fitness, Varun Jay Varadaraj, said, “At AIRLAB, we embrace the 'Train high, live low' ethos as a cornerstone of our training philosophy.
  • Speaking about the hypoxic solution provided by ATS - Altitude Training Systems, Ramesh Ponnuswami, Executive Director (OSEA), Elgi Equipments Limited, said, “ATS’s innovative hypoxic training solution proved to be the ideal choice for AIRLAB Fitness, enabling the creation of high-altitude training conditions that are essential for their fitness programs.
  • ATS provided the technology and expertise required to set up an effective altitude training environment, setting the fitness studio on a trajectory toward new heights of excellence.”